
At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.
Giulia Corradetti, MD, is a research scientist at Doheny Eye Institute.

At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

At the Envision Summit 2025 in San Juan, Puerto Rico, Giulia Corradetti, MD discussed AI applications in the identification and prediction of OCT structural biomarkers in intermediate AMD.

May 3rd 2026